You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
賽生藥業(06600.HK)「日達仙」獲新納入TACE治療臨床實踐指南
阿思達克 07-21 11:20
賽生藥業(06600.HK)公布,原研產品「日達仙」為代表的胸腺法,新納入《中國肝細胞癌經動脈化療栓塞(TACE)治療臨床實踐指南(2021年版)》中關於TACE聯合免疫治療以及圍手術期輔助用藥的部分。

原發性肝癌主要包括肝細胞癌、膽管細胞癌和混合型3種病理學類型,其中肝癌佔85%-90%。根據流行病學資料,中國肝癌年發病人數約37萬,位居中國惡性腫瘤發病率第4位,年死亡人數約32.6萬,位居中國惡性腫瘤死亡率第二位。病人確診時多為中晚期,常規治療手段的中位生存時間僅約10個月。因此,尋求新的有效治療手段,以及採取合理的多學科綜合治療策略,對中晚期肝癌進行有效治療是改善肝癌總體生存的關鍵。TACE被公認為是最常用的肝癌局部治療方法之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account